CFO of Glaukos Buys 20,000 Shares Amid China‑Japan Regulatory Push, Sending Bullish Signal to Investors

Insider Activity Highlights a Shift in Glaukos’ Capital Allocation Strategy

The latest Form 4 filed on August 7, 2026, shows SVP & Chief Financial Officer Thurman Alex R. purchasing 20,000 shares of Glaukos Corporation at the current market price of $182.00. The transaction follows a series of Rule 10b‑5‑1 trading‑plan trades that have been executed over the past month. While the purchase itself is modest relative to the company’s market cap—just 0.02 % of outstanding shares—it signals a renewed confidence from the CFO in the firm’s near‑term prospects, particularly as Glaukos’ stock price has surged 19 % over the past month and remains near its 52‑week high.

What This Means for Investors

R’s recent buying activity comes in the context of a broader pattern of balanced insider trading. Over the last six months, Glaukos insiders—including the CEO, CFO, and senior development officers—have alternated between selling large blocks of stock (often at premium prices) and replenishing their positions at lower valuations. This cyclical behaviour is typical of companies that are simultaneously investing in pipeline development and managing cash flow. For Glaukos, the timing of the CFO’s purchase coincides with the announcement that its nitric‑oxide‑donating glaucoma therapy, NCX 470, has secured regulatory progress in China and is slated for launch in Japan. The infusion of cash from these deals could accelerate commercialization and potentially generate the revenue growth needed to improve the company’s negative P/E ratio and bring the stock back to a valuation more aligned with its peers.

Profile of Thurman Alex R.

Thurman has been a key financial steward at Glaukos since 2023, overseeing capital allocation during a period of aggressive product development. His insider‑trading history reflects a disciplined approach: he routinely sells shares under a 10b‑5‑1 plan at market‑premium levels (e.g., $160 on July 16 and $155 on July 9), while simultaneously repurchasing at lower prices (e.g., $38.68 on several occasions). This pattern suggests a strategic use of the trading plan to maintain liquidity and confidence without appearing opportunistic. His most recent purchase of 20,000 shares at $182—well above the median price of his prior trades—indicates that he perceives a short‑term upside, likely linked to the regulatory milestones for NCX 470 and the potential for revenue acceleration in Asia.

Broader Insider Activity

Other insiders have also been active, with the CEO selling a sizable block (4,059 shares) on June 25 at $142.57 and the COO selling 19,573 shares at $143.54 earlier in the month. These sales are often counterbalanced by purchases, illustrating a dynamic balance between liquidity needs and long‑term commitment. The CFO’s recent buy is therefore not an outlier but part of a broader insider strategy that aligns with the company’s capital‑intensive research and development pipeline.

Takeaway for Market Participants

While Glaukos continues to trade at a steep discount to its growth prospects—its P/E remains negative and the stock lags behind peer valuations—insider buying from a senior financial officer is a bullish signal. The CFO’s purchase, timed with regulatory progress in high‑potential markets, suggests that senior management believes the next phase of product commercialization will materially improve cash flows. Investors should watch for a potential breakout as regulatory approvals converge, but remain mindful that the company’s valuation still hinges on successful execution of its clinical and commercial plans.